Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

Specimen Handling 134pembrolizumab 123Magnetic Resonance Spectroscopy 112Carboplatin 88Cyclophosphamide 82Biopsy 75Cisplatin 61Bevacizumab 59Paclitaxel 58Gemcitabine 57Nivolumab 53fludarabine 46Rituximab 41atezolizumab 39Pemetrexed 38Fluorouracil 38Docetaxel 38Dexamethasone 38Doxorubicin 35Radiotherapy 33Leucovorin 33Capecitabine 33venetoclax 32Prednisone 32Oxaliplatin 31Temozolomide 30130-nm albumin-bound paclitaxel 29Standard of Care 27Cetuximab 27durvalumab 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Epoetin Alfa × 30 days × Clear all
NCT05564390 2026-06-05

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡